A JAK2 interdomain linker relays epo receptor engagement signals to kinase activation

Lequn Zhao, Hongyun Dong, Chengcheng Zhang, Lisa Kinch, Mitsujiro Osawa, Michelina Iacovino, Nick V Grishin, Michael Kyba, Jun-Shen Huang

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

JAK2 (Janus kinase 2) is essential for cytokine receptor signaling, and several lines of evidence support a causal role of an activating JAK2 mutation in myeloproliferative disorders. JAK2 activity is autoinhibited by its pseudokinase domain in the basal state, and the inhibition is released by cytokine stimulation; how engagement of the cognate receptor triggers this release is unknown. From a functional screen for gain-of-function JAK2 mutations, we discovered 13 missense mutations, nine in the pseudokinase domain and four in the Src homology 2 (SH2)-pseudokinase domain linker. These mutations identified determinants for autoinhibition and inducible activation in JAK2. Twoof the mutants, K539I and N622I, resulted in erythrocytosis in mice. Scanning mutagenesis of the SH2-pseudokinase domain linker indicated that its N-terminal part was essential for interaction of JAK2 with the Epo receptor, whereas certain mutations in the C-terminal region conferred constitutive activation. We further showed that substitutions for Glu543-Asp544 in this linker or Leu611, Arg683, or Phe694 in the hinge proximal region of the pseudokinase domain resulted in activated JAK2 mutants that could not be further stimulated by Epo. These results suggest that the SH2-pseudokinase domain linker acts as a switch that relays cytokine engagement to JAK2 activation by flexing the pseudokinase domain hinge.

Original languageEnglish (US)
Pages (from-to)26988-26991
Number of pages4
JournalJournal of Biological Chemistry
Volume284
Issue number39
DOIs
StatePublished - Sep 25 2009

Fingerprint

Janus Kinase 2
Phosphotransferases
Chemical activation
Mutation
Hinges
Cytokines
Myeloproliferative Disorders
Polycythemia
Mutagenesis
Cytokine Receptors
Missense Mutation
Substitution reactions
Switches
Scanning

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Molecular Biology

Cite this

A JAK2 interdomain linker relays epo receptor engagement signals to kinase activation. / Zhao, Lequn; Dong, Hongyun; Zhang, Chengcheng; Kinch, Lisa; Osawa, Mitsujiro; Iacovino, Michelina; Grishin, Nick V; Kyba, Michael; Huang, Jun-Shen.

In: Journal of Biological Chemistry, Vol. 284, No. 39, 25.09.2009, p. 26988-26991.

Research output: Contribution to journalArticle

Zhao, Lequn ; Dong, Hongyun ; Zhang, Chengcheng ; Kinch, Lisa ; Osawa, Mitsujiro ; Iacovino, Michelina ; Grishin, Nick V ; Kyba, Michael ; Huang, Jun-Shen. / A JAK2 interdomain linker relays epo receptor engagement signals to kinase activation. In: Journal of Biological Chemistry. 2009 ; Vol. 284, No. 39. pp. 26988-26991.
@article{f320cb2c8dab4c8b8a7d3e1e30a0129c,
title = "A JAK2 interdomain linker relays epo receptor engagement signals to kinase activation",
abstract = "JAK2 (Janus kinase 2) is essential for cytokine receptor signaling, and several lines of evidence support a causal role of an activating JAK2 mutation in myeloproliferative disorders. JAK2 activity is autoinhibited by its pseudokinase domain in the basal state, and the inhibition is released by cytokine stimulation; how engagement of the cognate receptor triggers this release is unknown. From a functional screen for gain-of-function JAK2 mutations, we discovered 13 missense mutations, nine in the pseudokinase domain and four in the Src homology 2 (SH2)-pseudokinase domain linker. These mutations identified determinants for autoinhibition and inducible activation in JAK2. Twoof the mutants, K539I and N622I, resulted in erythrocytosis in mice. Scanning mutagenesis of the SH2-pseudokinase domain linker indicated that its N-terminal part was essential for interaction of JAK2 with the Epo receptor, whereas certain mutations in the C-terminal region conferred constitutive activation. We further showed that substitutions for Glu543-Asp544 in this linker or Leu611, Arg683, or Phe694 in the hinge proximal region of the pseudokinase domain resulted in activated JAK2 mutants that could not be further stimulated by Epo. These results suggest that the SH2-pseudokinase domain linker acts as a switch that relays cytokine engagement to JAK2 activation by flexing the pseudokinase domain hinge.",
author = "Lequn Zhao and Hongyun Dong and Chengcheng Zhang and Lisa Kinch and Mitsujiro Osawa and Michelina Iacovino and Grishin, {Nick V} and Michael Kyba and Jun-Shen Huang",
year = "2009",
month = "9",
day = "25",
doi = "10.1074/jbc.M109.011387",
language = "English (US)",
volume = "284",
pages = "26988--26991",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "39",

}

TY - JOUR

T1 - A JAK2 interdomain linker relays epo receptor engagement signals to kinase activation

AU - Zhao, Lequn

AU - Dong, Hongyun

AU - Zhang, Chengcheng

AU - Kinch, Lisa

AU - Osawa, Mitsujiro

AU - Iacovino, Michelina

AU - Grishin, Nick V

AU - Kyba, Michael

AU - Huang, Jun-Shen

PY - 2009/9/25

Y1 - 2009/9/25

N2 - JAK2 (Janus kinase 2) is essential for cytokine receptor signaling, and several lines of evidence support a causal role of an activating JAK2 mutation in myeloproliferative disorders. JAK2 activity is autoinhibited by its pseudokinase domain in the basal state, and the inhibition is released by cytokine stimulation; how engagement of the cognate receptor triggers this release is unknown. From a functional screen for gain-of-function JAK2 mutations, we discovered 13 missense mutations, nine in the pseudokinase domain and four in the Src homology 2 (SH2)-pseudokinase domain linker. These mutations identified determinants for autoinhibition and inducible activation in JAK2. Twoof the mutants, K539I and N622I, resulted in erythrocytosis in mice. Scanning mutagenesis of the SH2-pseudokinase domain linker indicated that its N-terminal part was essential for interaction of JAK2 with the Epo receptor, whereas certain mutations in the C-terminal region conferred constitutive activation. We further showed that substitutions for Glu543-Asp544 in this linker or Leu611, Arg683, or Phe694 in the hinge proximal region of the pseudokinase domain resulted in activated JAK2 mutants that could not be further stimulated by Epo. These results suggest that the SH2-pseudokinase domain linker acts as a switch that relays cytokine engagement to JAK2 activation by flexing the pseudokinase domain hinge.

AB - JAK2 (Janus kinase 2) is essential for cytokine receptor signaling, and several lines of evidence support a causal role of an activating JAK2 mutation in myeloproliferative disorders. JAK2 activity is autoinhibited by its pseudokinase domain in the basal state, and the inhibition is released by cytokine stimulation; how engagement of the cognate receptor triggers this release is unknown. From a functional screen for gain-of-function JAK2 mutations, we discovered 13 missense mutations, nine in the pseudokinase domain and four in the Src homology 2 (SH2)-pseudokinase domain linker. These mutations identified determinants for autoinhibition and inducible activation in JAK2. Twoof the mutants, K539I and N622I, resulted in erythrocytosis in mice. Scanning mutagenesis of the SH2-pseudokinase domain linker indicated that its N-terminal part was essential for interaction of JAK2 with the Epo receptor, whereas certain mutations in the C-terminal region conferred constitutive activation. We further showed that substitutions for Glu543-Asp544 in this linker or Leu611, Arg683, or Phe694 in the hinge proximal region of the pseudokinase domain resulted in activated JAK2 mutants that could not be further stimulated by Epo. These results suggest that the SH2-pseudokinase domain linker acts as a switch that relays cytokine engagement to JAK2 activation by flexing the pseudokinase domain hinge.

UR - http://www.scopus.com/inward/record.url?scp=70350351539&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350351539&partnerID=8YFLogxK

U2 - 10.1074/jbc.M109.011387

DO - 10.1074/jbc.M109.011387

M3 - Article

VL - 284

SP - 26988

EP - 26991

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 39

ER -